Scientific publications
Scientific publications of the Veneto Tumour Registry
Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015
Mancini S, Bucchi L, Baldacchini F, Giuliani O, Ravaioli A, Vattiato R, Preti M, Tumino R, Ferretti S, Biggeri A, Brustolin A, Boschetti L, Caiazzo AL, Caldarella A, Cesaraccio R, Cirilli C, Citarella A, Filiberti RA, Fusco M, Galasso R, Gatti L, Lotti FL, Magoni M, Mangone L, Masanotti G, Mazzoleni G, Mazzucco W, Melcarne A, Michiara M, Pesce P, Piffer S, Pinto A, Rognoni M, Rosso S, Rugge M, Sampietro G, Scalzi S, Scuderi T, Tagliabue G, Tisano F, Toffolutti F, Vitarelli S, Falcini F; AIRTUM Working Group. Gynecol Oncol. 2020 Apr 6. pii: S0090-8258(20)30229-8. doi:...
Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
Cuzick J, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Del Mistro A, Frayle H, Girlando S, Sani C, Confortini M, Zorzi M, Giorgi-Rossi P, Rizzolo R, Ronco G; New Technologies for Cervical Cancer Screening Working Group. Int J Cancer. 2020 Mar 14. doi: 10.1002/ijc.32973. [Epub ahead of print] Abstract Human papillomavirus (HPV) testing is very sensitive for primary cervical screening but has low specificity. Triage tests that improve specificity but maintain high sensitivity are needed. Women enrolled in the experimental arm of Phase 2 of the New Technologies for Cervical Cancer...
Association between acute histopathological changes of rectal walls and late radiation proctitis following radiotherapy for prostate cancer.
Campostrini F, Remo A, Astati L, Zorzi M, Capodaglio G, Buffoli A, Moretti G, Della Monica B, Zanella C, Verlato G. Strahlenther Onkol. 2020 Mar 12. doi: 10.1007/s00066-020-01590-3. [Epub ahead of print]
Real-world Strategies for Colorectal Cancer Screening Based on Studies From The Netherlands
Selby K, Zorzi M. Clin Gastroenterol Hepatol. 2020 Mar;18(3):546-547. doi: 10.1016/j.cgh.2019.09.013. Epub 2019 Sep 13.
Differences in direct costs of patients with stage I cutaneous melanoma: A real-world data analysis
Buja A, Rivera M, De Polo A, Zorzi M, Baracco M, Italiano I, Vecchiato A, Del Fiore P, Guzzinati S, Saia M, Baldo V, Rugge M, Rossi CR. Eur J Surg Oncol. 2020 Feb 19. pii: S0748-7983(20)30119-0. doi: 10.1016/j.ejso.2020.02.017. [Epub ahead of print] Review. Abstract BACKGROUND:Clinical factors, such as tumor thickness, ulceration and growth phase have a role as prognostic factors for stage I melanoma. However, it is still under debate whether these variables influence the related direct costs. We aimed to investigate which clinical factors represent direct health care "cost drivers" for...
Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates
Zorzi M, Zappa M; AIRTUM Working Group. Gut. 2020 Feb;69(2):311-316. doi: 10.1136/gutjnl-2019-318589. Epub 2019 Apr 30. Abstract OBJECTIVE:The impact of a screening programme on colorectal cancer (CRC) incidence in its target population depends on several variables, including coverage with invitations, participation rate, positivity rate of the screening test, compliance with an invitation to second-level assessment and endoscopists' sensitivity. We propose a synthetic indicator that may account for all the variables influencing the potential impact of a screening programme on CRC...
Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study
Bielska-Lasota M, Rossi S, Krzyżak M, Haelens A, Domenic A, De Angelis R, Maciejczyk A, Rodríguez-Barranco M, Zadnik V, Minicozzi P; EUROCARE-5 Working Group. Arch Gynecol Obstet. 2020 Feb;301(2):591-602. doi: 10.1007/s00404-019-05412-5. Epub 2019 Dec 18. Abstract PURPOSE:With better access to early diagnosis and appropriate treatment, cervical cancer (CC) burden decreased in several European countries. In Eastern European (EE) countries, which accessed European Union in 2004, CC survival was worse than in the rest of Europe. The present study investigates CC survival differences across...
Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: Concurrent cohorts with a 5-year follow-up
Zorzi M, Del Mistro A, Giorgi Rossi P, Laurino L, Battagello J, Lorio M, Soldà M, Martinotti Gabellotti E, Maran M, Dal Cin A, Fiore A, Rugge M, Maggino T. Int J Cancer. 2020 Jun 1;146(11):3114-3123. doi: 10.1002/ijc.32695. Epub 2019 Oct 15. Abstract Aim of this study was to compare the 5-year risk of cervical intraepithelial neoplasia grade 2+ (CIN2+)/CIN3+ and the performance parameters at 3-year rescreening of a negative E6/E7 mRNA-human papillomavirus (HPV) test with those of a HPV-DNA-negative test. We studied a cohort of HPV-negative women tested with the Aptima HPV-mRNA Assay...
Main topics
Scientific publications
Scientific publications of the Veneto Tumour Registry
Monographs
Reports by tumour site and monographs.
Congress and conference
Discover all the oral publications and posters.